For pediatric kids aged two to five with seizure clusters, Aquestive Therapeutics (AQST, Financials) said that the U.S. Food and Drug Administration has given seven years of orphan drug exclusivity to its medicine, Libervant (diazepam). Shares are up 6.7% on the news. In terms of simplicity of usage for patients and caregivers, the choice honors Libervant's buccal administration as a significant advance above the rectal method.
Approved for use in April 2024, Libervant is the first orally given rescue treatment for this patient population. The exclusivity spans April 2031, giving Aquestive market protection for the good throughout this month. Designed to control acute seizure events unique from a patient's normal pattern, the therapy provides a non-invasive substitute for current choices.
Originally assigned orphan drug classification for Libervant in 2016, Aquestive Orphan medication exclusivity offers financial incentives and legal benefits to help rare illness medicines be developed and commercialized. Libervant is a component of Aquestive's larger range of creative, orally delivered treatments meant for difficult medical problems.
The business said that its major priorities still include raising knowledge and access for caregivers and healthcare professionals. Emphasizing safety and simplicity of use, Libervant marks a major progress in the management of seizure episodes in young children.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。